Café

© 2026 Longbridge｜Terms of Service Privacy Policy

QNTM

QNTM

3.4400.00%( 0.000 )

LongbridgeAI

Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial

Unusual Whales

Aug 14, 2026 at 06:02 AM

In Toronto on August 14, 2026, Quantum BioPharma Ltd. (QNTM) released its financial and operational performance for the second quarter of 2026, concluding on June 30.

Source: Unusual Whales The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

Quantum Biopharma

QNTM.US

Open

--

High

--

Low

--

Prev Close

--

P/E^TTM

--

Market Cap

--